{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:02:51Z","timestamp":1793638971397,"version":"4.5.1"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Clinical Need Oriented Basic Research Project of Inner Mongolia Academy of Medical Sciences","award":["No. 2023GLLH0229"],"award-info":[{"award-number":["No. 2023GLLH0229"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glioma is the most common malignant tumor in central nervous system, with significant health burdens to patients. Due to the intrinsic characteristics of glioma and the lack of breakthroughs in treatment modalities, the prognosis for most patients remains poor. This results in a heavy psychological and financial load worldwide. In recent years, cannabidiol (CBD) has garnered widespread attention and research due to its anti-tumoral, anti-inflammatory, and neuroprotective properties. This review comprehensively summarizes the preclinical and clinical research on the use of CBD in glioma therapy, as well as the current status of nanomedicine formulations of CBD, and discusses the potential and challenges of CBD in glioma therapy in the future.<\/jats:p>","DOI":"10.1186\/s12967-024-05477-0","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T03:36:10Z","timestamp":1720668970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["From bench to bedside: the application of cannabidiol in glioma"],"prefix":"10.1186","volume":"22","author":[{"given":"Shiying","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1672-8035","authenticated-orcid":false,"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"issue":"1","key":"5477_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11060-011-0738-7","volume":"107","author":"M Koshy","year":"2012","unstructured":"Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012;107(1):207\u201312.","journal-title":"J Neurooncol"},{"issue":"1","key":"5477_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11060-018-03065-z","volume":"142","author":"P Fabbro-Peray","year":"2019","unstructured":"Fabbro-Peray P, Zouaoui S, Darlix A, Fabbro M, Pallud J, Rigau V, et al. Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. J Neurooncol. 2019;142(1):91\u2013101.","journal-title":"J Neurooncol"},{"issue":"1","key":"5477_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12967-023-04042-5","volume":"21","author":"X Hou","year":"2023","unstructured":"Hou X, Du H, Deng Y, Wang H, Liu J, Qiao J, et al. Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma. J Transl Med. 2023;21(1):198.","journal-title":"J Transl Med"},{"issue":"3","key":"5477_CR4","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3171\/2018.12.JNS182558","volume":"132","author":"TH Roh","year":"2019","unstructured":"Roh TH, Kang SG, Moon JH, Sung KS, Park HH, Kim SH, et al. Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a retrospective study. J Neurosurg. 2019;132(3):895\u2013901.","journal-title":"J Neurosurg"},{"issue":"5","key":"5477_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3322\/caac.21693","volume":"71","author":"KD Miller","year":"2021","unstructured":"Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71(5):381\u2013406.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"5477_CR6","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41416-021-01259-3","volume":"124","author":"C Twelves","year":"2021","unstructured":"Twelves C, Sabel M, Checketts D, Miller S, Tayo B, Jove M, et al. A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. Br J Cancer. 2021;124(8):1379\u201387.","journal-title":"Br J Cancer"},{"issue":"21","key":"5477_CR7","doi-asserted-by":"publisher","first-page":"12137","DOI":"10.1021\/acs.jmedchem.0c00724","volume":"63","author":"KM Nelson","year":"2020","unstructured":"Nelson KM, Bisson J, Singh G, Graham JG, Chen SN, Friesen JB, et al. The essential medicinal chemistry of Cannabidiol (CBD). J Med Chem. 2020;63(21):12137\u201355.","journal-title":"J Med Chem"},{"issue":"4","key":"5477_CR8","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/cancers12041033","volume":"12","author":"F Afrin","year":"2020","unstructured":"Afrin F, Chi M, Eamens AL, Duchatel RJ, Douglas AM, Schneider J, et al. Can Hemp Help? Low-THC Cannabis and Non-THC cannabinoids for the treatment of cancer. Cancers (Basel). 2020;12(4):1033.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"5477_CR9","first-page":"3799","volume":"31","author":"S Sreevalsan","year":"2011","unstructured":"Sreevalsan S, Joseph S, Jutooru I, Chadalapaka G, Safe SH. Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent. Anticancer Res. 2011;31(11):3799\u2013807.","journal-title":"Anticancer Res"},{"issue":"6","key":"5477_CR10","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nrc3247","volume":"12","author":"G Velasco","year":"2012","unstructured":"Velasco G, S\u00e1nchez C, Guzm\u00e1n M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436\u201344.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"5477_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","volume":"42","author":"F Grotenhermen","year":"2003","unstructured":"Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327\u201360.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"5477_CR12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/jnci\/55.3.597","volume":"55","author":"AE Munson","year":"1975","unstructured":"Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. Antineoplastic activity of cannabinoids. J Natl Cancer Inst. 1975;55(3):597\u2013602.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"5477_CR13","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.2174\/1381612822666151211094901","volume":"22","author":"MI Khan","year":"2016","unstructured":"Khan MI, Soboci\u0144ska AA, Czarnecka AM, Kr\u00f3l M, Botta B, Szczylik C. The therapeutic aspects of the endocannabinoid system (ECS) for cancer and their development: from nature to laboratory. Curr Pharm Des. 2016;22(12):1756\u201366.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"5477_CR14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00213-003-1739-9","volume":"174","author":"M Kwiatkowska","year":"2004","unstructured":"Kwiatkowska M, Parker LA, Burton P, Mechoulam R. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology. 2004;174(2):254\u20139.","journal-title":"Psychopharmacology"},{"issue":"8","key":"5477_CR15","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1111\/j.1476-5381.2011.01621.x","volume":"165","author":"EM Rock","year":"2012","unstructured":"Rock EM, Bolognini D, Limebeer CL, Cascio MG, Anavi-Goffer S, Fletcher PJ, et al. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol. 2012;165(8):2620\u201334.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"5477_CR16","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/bph.12439","volume":"171","author":"SJ Ward","year":"2014","unstructured":"Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Walker EA. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol. 2014;171(3):636\u201345.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"5477_CR17","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/j.1476-5381.2012.02050.x","volume":"167","author":"M Solinas","year":"2012","unstructured":"Solinas M, Massi P, Cantelmo AR, Cattaneo MG, Cammarota R, Bartolini D, et al. Cannabidiol inhibits angiogenesis by multiple mechanisms. Br J Pharmacol. 2012;167(6):1218\u201331.","journal-title":"Br J Pharmacol"},{"issue":"17","key":"5477_CR18","doi-asserted-by":"publisher","first-page":"9472","DOI":"10.3390\/ijms22179472","volume":"22","author":"H Lowe","year":"2021","unstructured":"Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The endocannabinoid system: a potential target for the treatment of various diseases. Int J Mol Sci. 2021;22(17):9472.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"5477_CR19","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/S0006-2952(00)00492-5","volume":"60","author":"SO Jacobsson","year":"2000","unstructured":"Jacobsson SO, Rong\u00e5rd E, Stridh M, Tiger G, Fowler CJ. Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol. 2000;60(12):1807\u201313.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"5477_CR20","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1124\/jpet.103.061002","volume":"308","author":"P Massi","year":"2004","unstructured":"Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther. 2004;308(3):838\u201345.","journal-title":"J Pharmacol Exp Ther"},{"issue":"17","key":"5477_CR21","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s00018-006-6156-x","volume":"63","author":"P Massi","year":"2006","unstructured":"Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P, Parolaro D. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci. 2006;63(17):2057\u201366.","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"5477_CR22","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1471-4159.2011.07625.x","volume":"120","author":"X Wu","year":"2012","unstructured":"Wu X, Han L, Zhang X, Li L, Jiang C, Qiu Y, et al. Alteration of endocannabinoid system in human gliomas. J Neurochem. 2012;120(5):842\u20139.","journal-title":"J Neurochem"},{"issue":"1","key":"5477_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1158\/1535-7163.MCT-09-0407","volume":"9","author":"JP Marcu","year":"2010","unstructured":"Marcu JP, Christian RT, Lau D, Zielinski AJ, Horowitz MP, Lee J, et al. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther. 2010;9(1):180\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"5477_CR24","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2174\/092986711794940888","volume":"18","author":"G Appendino","year":"2011","unstructured":"Appendino G, Chianese G, Taglialatela-Scafati O. Cannabinoids: occurrence and medicinal chemistry. Curr Med Chem. 2011;18(7):1085\u201399.","journal-title":"Curr Med Chem"},{"issue":"4","key":"5477_CR25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1111\/j.1471-4159.2007.05073.x","volume":"104","author":"P Massi","year":"2008","unstructured":"Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E, et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem. 2008;104(4):1091\u2013100.","journal-title":"J Neurochem"},{"issue":"11","key":"5477_CR26","first-page":"5827","volume":"35","author":"KA Scott","year":"2015","unstructured":"Scott KA, Dennis JL, Dalgleish AG, Liu WM. Inhibiting heat shock proteins can potentiate the cytotoxic effect of Cannabidiol in human glioma cells. Anticancer Res. 2015;35(11):5827\u201337.","journal-title":"Anticancer Res"},{"key":"5477_CR27","doi-asserted-by":"publisher","first-page":"725136","DOI":"10.3389\/fphar.2021.725136","volume":"12","author":"C Gross","year":"2021","unstructured":"Gross C, Ramirez DA, McGrath S, Gustafson DL. Cannabidiol induces apoptosis and perturbs mitochondrial function in human and canine glioma cells. Front Pharmacol. 2021;12:725136.","journal-title":"Front Pharmacol"},{"issue":"11","key":"5477_CR28","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1080\/15548627.2021.1885203","volume":"17","author":"T Huang","year":"2021","unstructured":"Huang T, Xu T, Wang Y, Zhou Y, Yu D, Wang Z, et al. Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4. Autophagy. 2021;17(11):3592\u2013606.","journal-title":"Autophagy"},{"issue":"13","key":"5477_CR29","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.3390\/cancers14133129","volume":"14","author":"A Rupprecht","year":"2022","unstructured":"Rupprecht A, Theisen U, Wendt F, Frank M, Hinz B. The combination of \u03b49-tetrahydrocannabinol and cannabidiol suppresses mitochondrial respiration of human glioblastoma cells via downregulation of specific respiratory chain proteins. Cancers (Basel). 2022;14(13):3129.","journal-title":"Cancers (Basel)"},{"key":"5477_CR30","doi-asserted-by":"publisher","first-page":"104823","DOI":"10.1016\/j.phrs.2020.104823","volume":"157","author":"M Markouli","year":"2020","unstructured":"Markouli M, Strepkos D, Papavassiliou AG, Piperi C. Targeting of endoplasmic reticulum (ER) stress in gliomas. Pharmacol Res. 2020;157:104823.","journal-title":"Pharmacol Res"},{"issue":"8","key":"5477_CR31","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/sj.bjp.0706134","volume":"144","author":"A Vaccani","year":"2005","unstructured":"Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol. 2005;144(8):1032\u20136.","journal-title":"Br J Pharmacol"},{"issue":"10","key":"5477_CR32","doi-asserted-by":"publisher","first-page":"e76918","DOI":"10.1371\/journal.pone.0076918","volume":"8","author":"M Solinas","year":"2013","unstructured":"Solinas M, Massi P, Cinquina V, Valenti M, Bolognini D, Gariboldi M, et al. Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect. PLoS ONE. 2013;8(10):e76918.","journal-title":"PLoS ONE"},{"issue":"5","key":"5477_CR33","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1158\/0008-5472.CAN-12-1943","volume":"73","author":"L Soroceanu","year":"2013","unstructured":"Soroceanu L, Murase R, Limbad C, Singer E, Allison J, Adrados I, et al. Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res. 2013;73(5):1559\u201369.","journal-title":"Cancer Res"},{"issue":"1","key":"5477_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/neuonc\/noac141","volume":"25","author":"D Messinger","year":"2023","unstructured":"Messinger D, Harris MK, Cummings JR, Thomas C, Yang T, Sweha SR, et al. Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma. Neuro Oncol. 2023;25(1):54\u201367.","journal-title":"Neuro Oncol"},{"key":"5477_CR35","doi-asserted-by":"publisher","first-page":"770561","DOI":"10.3389\/fonc.2021.770561","volume":"11","author":"BT Himes","year":"2021","unstructured":"Himes BT, Geiger PA, Ayasoufi K, Bhargav AG, Brown DA, Parney IF. Immunosuppression in Glioblastoma: current understanding and therapeutic implications. Front Oncol. 2021;11:770561.","journal-title":"Front Oncol"},{"issue":"1","key":"5477_CR36","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41467-023-35957-8","volume":"14","author":"S Zhou","year":"2023","unstructured":"Zhou S, Huang Y, Chen Y, Liu Y, Xie L, You Y, et al. Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma. Nat Commun. 2023;14(1):435.","journal-title":"Nat Commun"},{"issue":"5","key":"5477_CR37","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1089\/can.2021.0098","volume":"8","author":"H Khodadadi","year":"2023","unstructured":"Khodadadi H, Salles \u00c9L, Alptekin A, Mehrabian D, Rutkowski M, Arbab AS, et al. Inhalant Cannabidiol inhibits glioblastoma progression through regulation of tumor microenvironment. Cannabis Cannabinoid Res. 2023;8(5):824\u201334.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"3","key":"5477_CR38","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1073\/pnas.0307618100","volume":"101","author":"T Kondo","year":"2004","unstructured":"Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A. 2004;101(3):781\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"5477_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/ijms19010147","volume":"19","author":"I Manini","year":"2018","unstructured":"Manini I, Caponnetto F, Bartolini A, Ius T, Mariuzzi L, Di Loreto C, et al. Role of microenvironment in glioma invasion: what we learned from in vitro models. Int J Mol Sci. 2018;19(1):147.","journal-title":"Int J Mol Sci"},{"issue":"15\u201316","key":"5477_CR40","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.lfs.2011.04.022","volume":"89","author":"TR Alves","year":"2011","unstructured":"Alves TR, Lima FRS, Kahn SA, Lobo D, Dubois LGF, Soletti R, et al. Glioblastoma cells: a heterogeneous and fatal tumor interacting with the parenchyma. Life Sci. 2011;89(15\u201316):532\u20139.","journal-title":"Life Sci"},{"issue":"1","key":"5477_CR41","doi-asserted-by":"publisher","first-page":"e1601","DOI":"10.1038\/cddis.2014.566","volume":"6","author":"E Singer","year":"2015","unstructured":"Singer E, Judkins J, Salomonis N, Matlaf L, Soteropoulos P, McAllister S, et al. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. Cell Death Dis. 2015;6(1):e1601.","journal-title":"Cell Death Dis"},{"issue":"8","key":"5477_CR42","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/ijc.29573","volume":"137","author":"M Nabissi","year":"2015","unstructured":"Nabissi M, Morelli MB, Amantini C, Liberati S, Santoni M, Ricci-Vitiani L, et al. Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner. Int J Cancer. 2015;137(8):1855\u201369.","journal-title":"Int J Cancer"},{"issue":"11","key":"5477_CR43","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1093\/neuonc\/noab095","volume":"23","author":"MNM Volmar","year":"2021","unstructured":"Volmar MNM, Cheng J, Alenezi H, Richter S, Haug A, Hassan Z, et al. Cannabidiol converts NF-\u03baB into a tumor suppressor in glioblastoma with defined antioxidative properties. Neuro Oncol. 2021;23(11):1898\u2013910.","journal-title":"Neuro Oncol"},{"issue":"3","key":"5477_CR44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.critrevonc.2006.06.007","volume":"60","author":"C Nieder","year":"2006","unstructured":"Nieder C, Adam M, Molls M, Grosu AL. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol. 2006;60(3):181\u201393.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"5477_CR45","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jocn.2006.11.005","volume":"14","author":"MLH Wong","year":"2007","unstructured":"Wong MLH, Kaye AH, Hovens CM. Targeting malignant glioma survival signalling to improve clinical outcomes. J Clin Neurosci. 2007;14(4):301\u20138.","journal-title":"J Clin Neurosci"},{"issue":"1","key":"5477_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/carcin\/bgs328","volume":"34","author":"M Nabissi","year":"2013","unstructured":"Nabissi M, Morelli MB, Santoni M, Santoni G. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis. 2013;34(1):48\u201357.","journal-title":"Carcinogenesis"},{"issue":"1","key":"5477_CR47","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/1535-7163.MCT-10-0688","volume":"10","author":"S Torres","year":"2011","unstructured":"Torres S, Lorente M, Rodr\u00edguez-Forn\u00e9s F, Hern\u00e1ndez-Tiedra S, Salazar M, Garc\u00eda-Taboada E, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther. 2011;10(1):90\u2013103.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"5477_CR48","doi-asserted-by":"publisher","first-page":"e54795","DOI":"10.1371\/journal.pone.0054795","volume":"8","author":"DHP de la Ossa","year":"2013","unstructured":"de la Ossa DHP, Lorente M, Gil-Alegre ME, Torres S, Garc\u00eda-Taboada E, Aberturas MDR, et al. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. PLoS One. 2013;8(1):e54795.","journal-title":"PLoS One"},{"key":"5477_CR49","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fonc.2012.00073","volume":"2","author":"D Greene-Schloesser","year":"2012","unstructured":"Greene-Schloesser D, Robbins ME, Peiffer AM, Shaw EG, Wheeler KT, Chan MD. Radiation-induced brain injury: A review. Front Oncol. 2012;2:73.","journal-title":"Front Oncol"},{"issue":"14","key":"5477_CR50","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1158\/0008-5472.CAN-11-0027","volume":"71","author":"MM Acharya","year":"2011","unstructured":"Acharya MM, Christie LA, Lan ML, Giedzinski E, Fike JR, Rosi S, et al. Human neural stem cell transplantation ameliorates radiation-induced cognitive dysfunction. Cancer Res. 2011;71(14):4834\u201345.","journal-title":"Cancer Res"},{"issue":"12","key":"5477_CR51","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1158\/1535-7163.MCT-14-0402","volume":"13","author":"KA Scott","year":"2014","unstructured":"Scott KA, Dalgleish AG, Liu WM. The combination of cannabidiol and \u03949-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Mol Cancer Ther. 2014;13(12):2955\u201367.","journal-title":"Mol Cancer Ther"},{"issue":"43","key":"5477_CR52","doi-asserted-by":"publisher","first-page":"74068","DOI":"10.18632\/oncotarget.18240","volume":"8","author":"VN Ivanov","year":"2017","unstructured":"Ivanov VN, Wu J, Hei TK. Regulation of human glioblastoma cell death by combined treatment of cannabidiol, \u03b3-radiation and small molecule inhibitors of cell signaling pathways. Oncotarget. 2017;8(43):74068\u201395.","journal-title":"Oncotarget"},{"issue":"2","key":"5477_CR53","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/cells10020340","volume":"10","author":"TT Lah","year":"2021","unstructured":"Lah TT, Novak M, Pena Almidon MA, Marinelli O, \u017dvar Ba\u0161kovi\u010d B, Majc B, et al. Cannabigerol is a potential therapeutic agent in a novel combined therapy for glioblastoma. Cells. 2021;10(2):340.","journal-title":"Cells"},{"issue":"23","key":"5477_CR54","doi-asserted-by":"publisher","first-page":"5918","DOI":"10.3390\/cancers14235918","volume":"14","author":"TT Lah","year":"2022","unstructured":"Lah TT, Majc B, Novak M, Su\u0161nik A, Breznik B, Por\u010dnik A, et al. The cytotoxic effects of cannabidiol and cannabigerol on glioblastoma stem cells may mostly involve GPR55 and TRPV1 signalling. Cancers (Basel). 2022;14(23):5918.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"5477_CR55","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1083\/jcb.103.4.1495","volume":"103","author":"NC Collier","year":"1986","unstructured":"Collier NC, Schlesinger MJ. The dynamic state of heat shock proteins in chicken embryo fibroblasts. J Cell Biol. 1986;103(4):1495\u2013507.","journal-title":"J Cell Biol"},{"issue":"4","key":"5477_CR56","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1083\/jcb.106.4.1131","volume":"106","author":"NC Collier","year":"1988","unstructured":"Collier NC, Heuser J, Levy MA, Schlesinger MJ. Ultrastructural and biochemical analysis of the stress granule in chicken embryo fibroblasts. J Cell Biol. 1988;106(4):1131\u20139.","journal-title":"J Cell Biol"},{"issue":"1","key":"5477_CR57","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13578-023-01030-6","volume":"13","author":"H Zhou","year":"2023","unstructured":"Zhou H, Luo J, Mou K, Peng L, Li X, Lei Y, et al. Stress granules: functions and mechanisms in cancer. Cell Biosci. 2023;13(1):86.","journal-title":"Cell Biosci"},{"issue":"7","key":"5477_CR58","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.cell.2016.11.035","volume":"167","author":"E Grabocka","year":"2016","unstructured":"Grabocka E, Bar-Sagi D. Mutant KRAS enhances tumor cell fitness by upregulating stress granules. Cell. 2016;167(7):1803-1813.e12.","journal-title":"Cell"},{"issue":"6","key":"5477_CR59","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s12032-024-02381-x","volume":"41","author":"LP Wang","year":"2024","unstructured":"Wang LP, Chagas PS, Salles \u00c9L, Naeini SE, Gouron J, Rogers HM, et al. Altering biomolecular condensates as a potential mechanism that mediates cannabidiol effect on glioblastoma. Med Oncol. 2024;41(6):140.","journal-title":"Med Oncol"},{"key":"5477_CR60","doi-asserted-by":"publisher","first-page":"110995","DOI":"10.1016\/j.cbi.2024.110995","volume":"394","author":"NY Kim","year":"2024","unstructured":"Kim NY, Shivanne Gowda SG, Lee SG, Sethi G, Ahn KS. Cannabidiol induces ERK activation and ROS production to promote autophagy and ferroptosis in glioblastoma cells. Chem Biol Interact. 2024;394:110995.","journal-title":"Chem Biol Interact"},{"key":"5477_CR61","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.pnpbp.2015.05.010","volume":"64","author":"G Velasco","year":"2016","unstructured":"Velasco G, Hern\u00e1ndez-Tiedra S, D\u00e1vila D, Lorente M. The use of cannabinoids as anticancer agents. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:259\u201366.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"5477_CR62","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ccr.2006.03.005","volume":"9","author":"A Carracedo","year":"2006","unstructured":"Carracedo A, Lorente M, Egia A, Bl\u00e1zquez C, Garc\u00eda S, Giroux V, et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell. 2006;9(4):301\u201312.","journal-title":"Cancer Cell"},{"issue":"1","key":"5477_CR63","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1124\/jpet.116.236968","volume":"360","author":"L Deng","year":"2017","unstructured":"Deng L, Ng L, Ozawa T, Stella N. Quantitative analyses of synergistic responses between cannabidiol and DNA-damaging agents on the proliferation and viability of glioblastoma and neural progenitor cells in culture. J Pharmacol Exp Ther. 2017;360(1):215\u201324.","journal-title":"J Pharmacol Exp Ther"},{"issue":"67","key":"5477_CR64","doi-asserted-by":"publisher","first-page":"111581","DOI":"10.18632\/oncotarget.22875","volume":"8","author":"SH Kim","year":"2017","unstructured":"Kim SH, Kim KY, Park SG, Yu SN, Kim YW, Nam HW, et al. Mitochondrial ROS activates ERK\/autophagy pathway as a protected mechanism against deoxypodophyllotoxin-induced apoptosis. Oncotarget. 2017;8(67):111581\u201396.","journal-title":"Oncotarget"},{"issue":"6","key":"5477_CR65","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.3171\/2014.9.FOCUS14504","volume":"37","author":"EB Golden","year":"2014","unstructured":"Golden EB, Cho HY, Jahanian A, Hofman FM, Louie SG, Sch\u00f6nthal AH, et al. Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. Neurosurg Focus. 2014;37(6):E12.","journal-title":"Neurosurg Focus"},{"issue":"5","key":"5477_CR66","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.devcel.2018.02.014","volume":"44","author":"BE Fitzwalter","year":"2018","unstructured":"Fitzwalter BE, Towers CG, Sullivan KD, Andrysik Z, Hoh M, Ludwig M, et al. Autophagy inhibition mediates apoptosis sensitization in cancer therapy by relieving FOXO3a turnover. Dev Cell. 2018;44(5):555-565.e3.","journal-title":"Dev Cell"},{"issue":"2","key":"5477_CR67","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.taap.2010.12.007","volume":"251","author":"X Li","year":"2011","unstructured":"Li X, Wu WKK, Sun B, Cui M, Liu S, Gao J, et al. Dihydroptychantol A, a macrocyclic bisbibenzyl derivative, induces autophagy and following apoptosis associated with p53 pathway in human osteosarcoma U2OS cells. Toxicol Appl Pharmacol. 2011;251(2):146\u201354.","journal-title":"Toxicol Appl Pharmacol"},{"key":"5477_CR68","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.bcp.2018.08.023","volume":"157","author":"I L\u00f3pez-Valero","year":"2018","unstructured":"L\u00f3pez-Valero I, Torres S, Salazar-Roa M, Garc\u00eda-Taboada E, Hern\u00e1ndez-Tiedra S, Guzm\u00e1n M, et al. Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma. Biochem Pharmacol. 2018;157:275\u201384.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"5477_CR69","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/cdd.2010.191","volume":"18","author":"R Kang","year":"2011","unstructured":"Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011;18(4):571\u201380.","journal-title":"Cell Death Differ"},{"issue":"12","key":"5477_CR70","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/onc.2009.519","volume":"29","author":"M Djavaheri-Mergny","year":"2010","unstructured":"Djavaheri-Mergny M, Maiuri MC, Kroemer G. Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene. 2010;29(12):1717\u20139.","journal-title":"Oncogene"},{"issue":"10","key":"5477_CR71","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41419-018-1003-1","volume":"9","author":"S Zielke","year":"2018","unstructured":"Zielke S, Meyer N, Mari M, Abou-El-Ardat K, Reggiori F, van Wijk SJL, et al. Loperamide, pimozide, and STF-62247 trigger autophagy-dependent cell death in glioblastoma cells. Cell Death Dis. 2018;9(10):994.","journal-title":"Cell Death Dis"},{"issue":"1","key":"5477_CR72","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1215\/15228517-2006-025","volume":"9","author":"KV Ballman","year":"2007","unstructured":"Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 2007;9(1):29\u201338.","journal-title":"Neuro Oncol"},{"issue":"10","key":"5477_CR73","doi-asserted-by":"publisher","first-page":"5831","DOI":"10.21873\/anticanres.12924","volume":"38","author":"J Kenyon","year":"2018","unstructured":"Kenyon J, Liu W, Dalgleish A. Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. Anticancer Res. 2018;38(10):5831\u20135.","journal-title":"Anticancer Res"},{"issue":"6","key":"5477_CR74","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/CCO.0000000000000876","volume":"34","author":"PB van der Meer","year":"2022","unstructured":"van der Meer PB, Taphoorn MJB, Koekkoek JAF. Management of epilepsy in brain tumor patients. Curr Opin Oncol. 2022;34(6):685\u201390.","journal-title":"Curr Opin Oncol"},{"key":"5477_CR75","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/B978-0-12-802997-8.00016-5","volume":"134","author":"DJ Englot","year":"2016","unstructured":"Englot DJ, Chang EF, Vecht CJ. Epilepsy and brain tumors. Handb Clin Neurol. 2016;134:267\u201385.","journal-title":"Handb Clin Neurol"},{"issue":"7","key":"5477_CR76","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/neuonc\/not057","volume":"15","author":"M Kerkhof","year":"2013","unstructured":"Kerkhof M, Dielemans JCM, van Breemen MS, Zwinkels H, Walchenbach R, Taphoorn MJ, et al. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol. 2013;15(7):961\u20137.","journal-title":"Neuro Oncol"},{"issue":"1","key":"5477_CR77","first-page":"40","volume":"8","author":"J Jo","year":"2021","unstructured":"Jo J, Nevel K, Sutyla R, Smolkin M, Lopes MB, Schiff D. Predictors of early, recurrent, and intractable seizures in low-grade glioma. Neurooncol Pract. 2021;8(1):40\u20137.","journal-title":"Neurooncol Pract"},{"issue":"4","key":"5477_CR78","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1097\/00006123-200010000-00001","volume":"47","author":"H Duffau","year":"2000","unstructured":"Duffau H, Capelle L, Lopes M, Faillot T, Sichez JP, Fohanno D. The insular lobe: physiopathological and surgical considerations. Neurosurgery. 2000;47(4):801\u201310.","journal-title":"Neurosurgery"},{"issue":"3","key":"5477_CR79","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3390\/cancers13030450","volume":"13","author":"P Baumgarten","year":"2021","unstructured":"Baumgarten P, Sarlak M, Monden D, Spyrantis A, Bernatz S, Gessler F, et al. Early and late postoperative seizures in meningioma patients and prediction by a recent scoring system. Cancers (Basel). 2021;13(3):450.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"5477_CR80","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/neuros\/nyx486","volume":"83","author":"DD Wang","year":"2018","unstructured":"Wang DD, Deng H, Hervey-Jumper SL, Molinaro AA, Chang EF, Berger MS. Seizure outcome after surgical resection of insular glioma. Neurosurgery. 2018;83(4):709\u201318.","journal-title":"Neurosurgery"},{"issue":"2","key":"5477_CR81","first-page":"105","volume":"9","author":"PB van der Meer","year":"2022","unstructured":"van der Meer PB, Dirven L, van den Bent MJ, Preusser M, Taphoorn MJB, Rud\u00e1 R, et al. Prescription preferences of antiepileptic drugs in brain tumor patients: an international survey among EANO members. Neurooncol Pract. 2022;9(2):105\u201313.","journal-title":"Neurooncol Pract"},{"issue":"5","key":"5477_CR82","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jamaneurol.2020.0032","volume":"77","author":"BAA Alsfouk","year":"2020","unstructured":"Alsfouk BAA, Brodie MJ, Walters M, Kwan P, Chen Z. Tolerability of antiseizure medications in individuals with newly diagnosed epilepsy. JAMA Neurol. 2020;77(5):574\u201381.","journal-title":"JAMA Neurol"},{"issue":"5\u20136","key":"5477_CR83","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/13554794.2017.1391294","volume":"23","author":"PP Warren","year":"2017","unstructured":"Warren PP, Bebin EM, Nabors LB, Szaflarski JP. The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy. Neurocase. 2017;23(5\u20136):287\u201391.","journal-title":"Neurocase"},{"key":"5477_CR84","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yebeh.2019.03.042","volume":"95","author":"JP Szaflarski","year":"2019","unstructured":"Szaflarski JP, Hernando K, Bebin EM, Gaston TE, Grayson LE, Ampah SB, et al. Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol. Epilepsy Behav. 2019;95:131\u20136.","journal-title":"Epilepsy Behav"},{"issue":"6","key":"5477_CR85","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","volume":"51","author":"MHJ van den Beuken-van Everdingen","year":"2016","unstructured":"van den Beuken-van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, Tjan-Heijnen VCG, Janssen DJA. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manag. 2016;51(6):1070-1090.e9.","journal-title":"J Pain Symptom Manag"},{"issue":"1","key":"5477_CR86","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1080\/00325481.2019.1685298","volume":"132","author":"A Capano","year":"2020","unstructured":"Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020;132(1):56\u201361.","journal-title":"Postgrad Med"},{"issue":"11","key":"5477_CR87","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.annonc.2020.07.020","volume":"31","author":"P Grimison","year":"2020","unstructured":"Grimison P, Mersiades A, Kirby A, Lintzeris N, Morton R, Haber P, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol. 2020;31(11):1553\u201360.","journal-title":"Ann Oncol"},{"issue":"6","key":"5477_CR88","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.3390\/ijms23063344","volume":"23","author":"C Pagano","year":"2022","unstructured":"Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C. Cannabinoids: therapeutic use in clinical practice. Int J Mol Sci. 2022;23(6):3344.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"5477_CR89","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jpainsymman.2009.06.008","volume":"39","author":"JR Johnson","year":"2010","unstructured":"Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manag. 2010;39(2):167\u201379.","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"5477_CR90","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jpainsymman.2017.09.001","volume":"55","author":"AH Lichtman","year":"2018","unstructured":"Lichtman AH, Lux EA, McQuade R, Rossetti S, Sanchez R, Sun W, et al. Results of a double-blind, randomized, placebo-controlled study of Nabiximols Oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manag. 2018;55(2):179-188.e1.","journal-title":"J Pain Symptom Manag"},{"issue":"3","key":"5477_CR91","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/2049463717710042","volume":"11","author":"MT Fallon","year":"2017","unstructured":"Fallon MT, Albert Lux E, McQuade R, Rossetti S, Sanchez R, Sun W, et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. Br J Pain. 2017;11(3):119\u201333.","journal-title":"Br J Pain"},{"issue":"2","key":"5477_CR92","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jpainsymman.2012.07.014","volume":"46","author":"JR Johnson","year":"2013","unstructured":"Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC\/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manag. 2013;46(2):207\u201318.","journal-title":"J Pain Symptom Manag"},{"issue":"5","key":"5477_CR93","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1365-2044.2004.03674.x","volume":"59","author":"W Notcutt","year":"2004","unstructured":"Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 \u201cN of 1\u201d studies. Anaesthesia. 2004;59(5):440\u201352.","journal-title":"Anaesthesia"},{"issue":"5","key":"5477_CR94","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jpain.2012.01.003","volume":"13","author":"RK Portenoy","year":"2012","unstructured":"Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438\u201349.","journal-title":"J Pain"},{"issue":"3","key":"5477_CR95","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40262-015-0319-6","volume":"55","author":"MO Jacus","year":"2016","unstructured":"Jacus MO, Daryani VM, Harstead KE, Patel YT, Throm SL, Stewart CF. Pharmacokinetic properties of anticancer agents for the treatment of central nervous system tumors: update of the literature. Clin Pharmacokinet. 2016;55(3):297\u2013311.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"5477_CR96","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1021\/acs.molpharmaceut.3c00244","volume":"21","author":"MT Chevalier","year":"2024","unstructured":"Chevalier MT, Al-Waeel M, Alsharabasy AM, Rebelo AL, Martin-Salda\u00f1a S, Pandit A. Therapeutic polymer-based cannabidiol formulation: tackling neuroinflammation associated with ischemic events in the brain. Mol Pharm. 2024;21(4):1609\u201324.","journal-title":"Mol Pharm"},{"issue":"9","key":"5477_CR97","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1097\/j.pain.0000000000001896","volume":"161","author":"CD Verrico","year":"2020","unstructured":"Verrico CD, Wesson S, Konduri V, Hofferek CJ, Vazquez-Perez J, Blair E, et al. A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain. 2020;161(9):2191\u2013202.","journal-title":"Pain"},{"issue":"5","key":"5477_CR98","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.3390\/polym12051172","volume":"12","author":"D Momekova","year":"2020","unstructured":"Momekova D, Ivanov E, Konstantinov S, Ublekov F, Petrov PD. Nanocomposite cryogel carriers from 2-hydroxyethyl cellulose network and cannabidiol-loaded polymeric micelles for sustained topical delivery. Polymers (Basel). 2020;12(5):1172.","journal-title":"Polymers (Basel)"},{"issue":"5","key":"5477_CR99","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/pharmaceutics12050439","volume":"12","author":"AI Fraguas-S\u00e1nchez","year":"2020","unstructured":"Fraguas-S\u00e1nchez AI, Torres-Su\u00e1rez AI, Cohen M, Delie F, Bastida-Ruiz D, Yart L, et al. PLGA Nanoparticles for the intraperitoneal administration of CBD in the treatment of ovarian cancer: in Vitro and in Ovo assessment. Pharmaceutics. 2020;12(5):439.","journal-title":"Pharmaceutics"},{"issue":"10","key":"5477_CR100","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1039\/D0TB02780D","volume":"9","author":"A Sharma","year":"2021","unstructured":"Sharma A, Kumar A, Li C, Panwar Hazari P, Mahajan SD, Aalinkeel R, et al. A cannabidiol-loaded Mg-gallate metal-organic framework-based potential therapeutic for glioblastomas. J Mater Chem B. 2021;9(10):2505\u201314.","journal-title":"J Mater Chem B"},{"key":"5477_CR101","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejpb.2018.11.020","volume":"134","author":"J Aparicio-Blanco","year":"2019","unstructured":"Aparicio-Blanco J, Sebasti\u00e1n V, Benoit JP, Torres-Su\u00e1rez AI. Lipid nanocapsules decorated and loaded with cannabidiol as targeted prolonged release carriers for glioma therapy: in vitro screening of critical parameters. Eur J Pharm Biopharm. 2019;134:126\u201337.","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"5477_CR102","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1021\/acs.molpharmaceut.8b01344","volume":"16","author":"J Aparicio-Blanco","year":"2019","unstructured":"Aparicio-Blanco J, Romero IA, Male DK, Slowing K, Garc\u00eda-Garc\u00eda L, Torres-Su\u00e1rez AI. Cannabidiol enhances the passage of lipid nanocapsules across the blood-brain barrier both in Vitro and in Vivo. Mol Pharm. 2019;16(5):1999\u20132010.","journal-title":"Mol Pharm"},{"issue":"8","key":"5477_CR103","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.3390\/pharmaceutics15082104","volume":"15","author":"J Ku\u017ami\u0144ska","year":"2023","unstructured":"Ku\u017ami\u0144ska J, Sobczak A, Majchrzak-Celi\u0144ska A, \u017b\u00f3\u0142nowska I, Gosty\u0144ska A, Jadach B, et al. Etoricoxib-cannabidiol combo: potential role in glioblastoma treatment and development of PLGA-based nanoparticles. Pharmaceutics. 2023;15(8):2104.","journal-title":"Pharmaceutics"},{"key":"5477_CR104","doi-asserted-by":"publisher","first-page":"145514","DOI":"10.1016\/j.cej.2023.145514","volume":"473","author":"Y Sun","year":"2023","unstructured":"Sun Y, Kong J, Ge X, Mao M, Yu H, Liu J, et al. A dual receptor targeting and blood\u2013brain barrier penetrating co-drug-loaded particle mediating inhibition of oxidative phosphorylation for targeted therapy of glioblastoma. Chem Eng J. 2023;473:145514.","journal-title":"Chem Eng J"},{"issue":"6","key":"5477_CR105","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s11095-014-1593-y","volume":"32","author":"T Yang","year":"2015","unstructured":"Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, et al. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm Res. 2015;32(6):2003\u201314.","journal-title":"Pharm Res"},{"issue":"7","key":"5477_CR106","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.tibtech.2017.03.004","volume":"35","author":"NL Syn","year":"2017","unstructured":"Syn NL, Wang L, Chow EKH, Lim CT, Goh BC. Exosomes in cancer nanomedicine and immunotherapy: prospects and challenges. Trends Biotechnol. 2017;35(7):665\u201376.","journal-title":"Trends Biotechnol"},{"key":"5477_CR107","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejim.2023.07.029","volume":"118","author":"C St\u00f6llberger","year":"2023","unstructured":"St\u00f6llberger C, Finsterer J. Cannabidiol\u2019s impact on drug-metabolization. Eur J Intern Med. 2023;118:6\u201313.","journal-title":"Eur J Intern Med"},{"issue":"8","key":"5477_CR108","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","volume":"56","author":"AL Geffrey","year":"2015","unstructured":"Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246\u201351.","journal-title":"Epilepsia"},{"issue":"2","key":"5477_CR109","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/pharmaceutics13020148","volume":"13","author":"M Deodhar","year":"2021","unstructured":"Deodhar M, Rihani SBA, Darakjian L, Turgeon J, Michaud V. Assessing the mechanism of fluoxetine-mediated CYP2D6 inhibition. Pharmaceutics. 2021;13(2):148.","journal-title":"Pharmaceutics"},{"issue":"12","key":"5477_CR110","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1530\/EC-18-0428","volume":"7","author":"A Jouinot","year":"2018","unstructured":"Jouinot A, Royer B, Chatelut E, Moeung S, Assi\u00e9 G, Thomas-Schoemann A, et al. Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study. Endocr Connect. 2018;7(12):1409\u201314.","journal-title":"Endocr Connect"},{"issue":"6","key":"5477_CR111","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/bcp.13574","volume":"84","author":"P Riera","year":"2018","unstructured":"Riera P, Salazar J, Virgili AC, Tobe\u00f1a M, Sebio A, Gallano P, et al. Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity. Br J Clin Pharmacol. 2018;84(6):1389\u201392.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"5477_CR112","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.bcp.2005.12.033","volume":"71","author":"ML Holland","year":"2006","unstructured":"Holland ML, Panetta JA, Hoskins JM, Bebawy M, Roufogalis BD, Allen JD, et al. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem Pharmacol. 2006;71(8):1146\u201354.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"5477_CR113","doi-asserted-by":"publisher","first-page":"723","DOI":"10.21873\/anticanres.15530","volume":"42","author":"SD Lustig","year":"2022","unstructured":"Lustig SD, Kodali SK, Longo SL, Kundu S, Viapiano MS. Ko143 Reverses MDR in glioblastoma via deactivating P-glycoprotein, sensitizing a resistant phenotype to TMZ treatment. Anticancer Res. 2022;42(2):723\u201330.","journal-title":"Anticancer Res"},{"issue":"1","key":"5477_CR114","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/cbdd.13758","volume":"97","author":"SB Syed","year":"2021","unstructured":"Syed SB, Lin SY, Arya H, Fu IH, Yeh TK, Charles MRC, et al. Overcoming vincristine resistance in cancer: computational design and discovery of piperine-inspired P-glycoprotein inhibitors. Chem Biol Drug Des. 2021;97(1):51\u201366.","journal-title":"Chem Biol Drug Des"},{"issue":"1","key":"5477_CR115","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/cts.13425","volume":"16","author":"JC Arnold","year":"2023","unstructured":"Arnold JC, McCartney D, Suraev A, McGregor IS. The safety and efficacy of low oral doses of cannabidiol: an evaluation of the evidence. Clin Transl Sci. 2023;16(1):10\u201330.","journal-title":"Clin Transl Sci"},{"issue":"10","key":"5477_CR116","doi-asserted-by":"publisher","first-page":"974","DOI":"10.2174\/1570159X17666190603171901","volume":"17","author":"MA Huestis","year":"2019","unstructured":"Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busard\u00f2 FP. Cannabidiol adverse effects and toxicity. Curr Neuropharmacol. 2019;17(10):974\u201389.","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"5477_CR117","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40263-022-00898-1","volume":"36","author":"A Strzelczyk","year":"2022","unstructured":"Strzelczyk A, Schubert-Bast S. A practical guide to the treatment of dravet syndrome with anti-seizure medication. CNS Drugs. 2022;36(3):217\u201337.","journal-title":"CNS Drugs"},{"issue":"14","key":"5477_CR118","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.3390\/jcm12144620","volume":"12","author":"M Wici\u0144ski","year":"2023","unstructured":"Wici\u0144ski M, Fajkiel-Madajczyk A, Kurant Z, Gryczka K, Kurant D, Szambelan M, et al. The use of cannabidiol in metabolic syndrome-an opportunity to improve the patient\u2019s health or much ado about nothing? J Clin Med. 2023;12(14):4620.","journal-title":"J Clin Med"},{"key":"5477_CR119","doi-asserted-by":"publisher","first-page":"102935","DOI":"10.1016\/j.drugpo.2020.102935","volume":"85","author":"IS McGregor","year":"2020","unstructured":"McGregor IS, Cairns EA, Abelev S, Cohen R, Henderson M, Couch D, et al. Access to cannabidiol without a prescription: A cross-country comparison and analysis. Int J Drug Policy. 2020;85:102935.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"5477_CR120","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S2215-0366(20)30074-2","volume":"7","author":"G Hindley","year":"2020","unstructured":"Hindley G, Beck K, Borgan F, Ginestet CE, McCutcheon R, Kleinloog D, et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry. 2020;7(4):344\u201353.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"5477_CR121","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/can.2017.0047","volume":"3","author":"C Beale","year":"2018","unstructured":"Beale C, Broyd SJ, Chye Y, Suo C, Schira M, Galettis P, et al. Prolonged cannabidiol treatment effects on hippocampal subfield volumes in current cannabis users. Cannabis Cannabinoid Res. 2018;3(1):94\u2013107.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"6","key":"5477_CR122","first-page":"31","volume":"14","author":"S Shannon","year":"2015","unstructured":"Shannon S, Opila-Lehman J. Cannabidiol oil for decreasing addictive use of marijuana: a case report. Integr Med (Encinitas). 2015;14(6):31\u20135.","journal-title":"Integr Med (Encinitas)"},{"issue":"9","key":"5477_CR123","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.mayocp.2019.01.003","volume":"94","author":"HJ VanDolah","year":"2019","unstructured":"VanDolah HJ, Bauer BA, Mauck KF. Clinicians\u2019 guide to cannabidiol and hemp oils. Mayo Clin Proc. 2019;94(9):1840\u201351.","journal-title":"Mayo Clin Proc"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05477-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05477-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05477-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T04:07:47Z","timestamp":1720670867000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05477-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":123,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5477"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05477-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"648"}}